To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
ProLectin M is an orally administered polysaccharide. Polysaccharides competitively bind to
the N-terminal tail of human galectin-3 through a proline isomerization [10]. Galetin-3
(Gal-3) is 1 among the 15 galectins described in humans and also a ubiquitous human galectin
expressed in various disease pathogenesis pathways [11].
The objective of this clinical study is to evaluate the safety and efficacy of a galectin
antagonist, ProLectin M (a Guar Gum Galactomannan), in the treatment of subjects with
asymptomatic to moderately-severe, ambulatory COVID-19 patients.